Gold prices steady ahead of Fed decision, Trump’s tariff deadline
Investing.com -- President Donald Trump’s nominee for the FDA Commissioner, Dr. Marty Makary, faced a Senate confirmation hearing today. During the hearing, Makary pledged to take a comprehensive look at the data the FDA collects on the use of the abortion pill, mifepristone. He also clarified that he has no preconceived plans for the mifepristone policy. Instead, he intends to conduct a thorough review if confirmed as the FDA Commissioner.
Makary also expressed his intention to reassess which topics necessitate the convening of the FDA vaccine advisory committee. Addressing rumors about Secretary Kennedy’s views on the removal of members from the Vaccine Advisory Committee, Makary clarified that Kennedy is primarily focused on improving America’s health, and has no such plans. He confirmed that he currently has no plans to remove anyone from any committees.
Furthermore, Makary assured the Senate that if confirmed, Vaccine Advisory Committee meetings will be held. He also committed to conducting a personal evaluation of the FDA’s staffing and personnel.
Regarding generic drug sales, Makary expressed a strong desire to collaborate with Congress on patent law to support generic drug manufacturers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.